Minimal Disseminated Disease Continues to Impact Outcomes Even in the Era of Targeted Therapy in Childhood ALK+ Anaplastic Large Cell Lymphoma, What More Do We Have to Offer?

Keywords

ALK - anaplastic large cell lymphoma - minimal disseminated disease - minimal residual disease - targeted therapy

Publication History

Received: 14 December 2023

Accepted: 26 June 2024

Article published online:
10 July 2024

• References

• 1 Mussolin L, Le Deley MC, Carraro E. et al. Prognostic factors in childhood anaplastic large cell lymphoma: long term results of the international ALCL99 trial. Cancers (Basel) 2020; 12 (10) 2747
• 2 Lowe EJ, Reilly AF, Lim MS. et al. Crizotinib in combination with chemotherapy for pediatric patients with ALK1 anaplastic large-cell lymphoma: the results of Children's Oncology Group Trial ANHL12P1. J Clin Oncol 2023; 41 (11) 2043-2053
• 3 Lowe EJ, Reilly AF, Lim MS. et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood 2021; 137 (26) 3595-3603
• 4 Damm-Welk C, Mussolin L, Zimmermann M. et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2014; 123 (03) 334-337
• 5 Damm-Welk C, Kutscher N, Zimmermann M. et al. Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma. Haematologica 2020; 105 (08) 2141-2149
• 6 Damm-Welk C, Busch K, Burkhardt B. et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2007; 110 (02) 670-677
• 7 Rigaud C, Abbas R, Grand D. et al. Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?. Pediatr Blood Cancer 2021; 68 (06) e28982
• 8 Mathew B, Vijayasekharan K, Shah S. et al. Prognostic value of 18F-FDG PET/CT-metabolic parameters at baseline and interim assessment in pediatric anaplastic large cell lymphoma. Clin Nucl Med 2020; 45 (03) 182-186
• 9 Hebart H, Lang P, Woessmann W. Nivolumab for refractory anaplastic large cell lymphoma: a case report. Ann Intern Med 2016; 165 (08) 607-608
• 10 Rigaud C, Abbou S, Ducassou S. et al. Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement. Haematologica 2022; 107 (09) 2255-2260
• 11 Liu W, Wu J, Ming X. et al. Case report: the utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL. Front Immunol 2024; 15: 1346001
• 12 Le Deley MC, Rosolen A, Williams DM. et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010; 28 (25) 3987-3993
• 13 Woessmann W, Zimmermann M, Lenhard M. et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 2011; 29 (22) 3065-3071
• 14 Knörr F, Brugières L, Pillon M. et al; European Inter-Group for Childhood Non-Hodgkin Lymphoma. Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol 2020; 38 (34) 3999-4009
• 15 Ramos CA, Ballard B, Zhang H. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest 2017; 127 (09) 3462-3471
• 16 Ramos CA, Grover NS, Beaven AW. et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2020; 38 (32) 3794-3804